RxDoctor Payments Data

Vonda Gravely, MD

Psychiatry · Spartanburg, SCNPI 1053382259

Payments from drug & device makers

$4,373in general payments, 2019–2025

Across 320 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Alkermes, Inc.$547
  • Johnson & Johnson$532
  • Otsuka America Pharmaceutical, Inc.$523
  • Neurocrine Biosciences, Inc.$374
  • AbbVie$222
  • plus $553 from 7 others

What the payments were for

  • Food & beverage$4,11094%
  • Education$2626%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,373 in reported general payments places this provider in the 85th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$13,007
Medicare patients
39
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate156$484,805
IngrezzaValbenazine Tosylate18$149,075
VraylarCariprazine Hcl50$74,077
Abilify MaintenaAripiprazole25$68,820
Clozapine OdtClozapine11$25,432
CaplytaLumateperone Tosylate13$21,721
Clozapine126$14,800
Aripiprazole127$12,686
Paliperidone ErPaliperidone64$9,613
Divalproex Sodium ErDivalproex Sodium108$7,396
Quetiapine Fumarate ErQuetiapine Fumarate27$6,351
Olanzapine153$4,179
Lurasidone Hcl45$4,098
Haloperidol Decanoate53$3,573
Quetiapine Fumarate142$3,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$532$484,805156 claims
Neurocrine Biosciences, Inc.Ingrezza$374$149,07518 claims
AbbVieVraylar$222$74,07750 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$523$68,82025 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$174$21,72113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →